GAIN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.96 USD | +1.02% |
|
-2.31% | -9.34% |
| 04-24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
| 04-08 | Gain Therapeutics Names Gene Mack as CFO | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 64.51 | 37.19 | 49.38 | 53.43 | - | - |
| Enterprise Value (EV) 1 | 64.51 | 37.19 | 49.38 | 53.43 | 53.43 | 53.43 |
| P/E ratio | -3.96 x | -2.11 x | -1.91 x | -2.59 x | -2.51 x | -1.8 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 391 x | 265 x | 895 x | 80.2 x | 372 x | 475 x |
| EV / Revenue | 391 x | 265 x | 895 x | 80.2 x | 372 x | 475 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | -5,177,177 x | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 11,880 | 11,883 | 15,123 | 18,052 | - | - |
| Reference price 2 | 5.430 | 3.130 | 3.265 | 2.960 | 2.960 | 2.960 |
| Announcement Date | 22-03-24 | 23-03-23 | 24-03-26 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.0289 | 0.165 | 0.1401 | 0.0552 | 0.666 | 0.1438 | 0.1125 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -13.83 | -17.78 | -22.25 | -22.07 | -28.93 | -38.81 |
| Operating Margin | - | -8,380% | -12,687.92% | -40,328.25% | -3,313.59% | -20,125.57% | -34,500.89% |
| Earnings before Tax (EBT) 1 | - | -13.89 | -17.5 | -22.19 | -21.83 | -28.56 | -38.76 |
| Net income 1 | - | -13.89 | -17.59 | -22.27 | -21.85 | -28.58 | -38.77 |
| Net margin | - | -8,419.06% | -12,554.95% | -40,354.33% | -3,281.04% | -19,885.22% | -34,465.33% |
| EPS 2 | -1.170 | -1.370 | -1.480 | -1.710 | -1.145 | -1.178 | -1.645 |
| Free Cash Flow | - | -12.46 | - | - | - | - | - |
| FCF margin | - | -7,551.9% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 21-03-15 | 22-03-24 | 23-03-23 | 24-03-26 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.0274 | 0.0432 | 0.045 | 0.0951 | - | - | 0.0552 | - | - | - | 0.09 | 0.095 | 0.0975 | 0.1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.636 | -3.209 | -3.288 | -5.176 | -4.751 | -4.561 | -5.23 | -7.731 | -4.885 | -4.407 | -5.16 | -5.575 | -6.301 | -6.82 |
| Operating Margin | -16,950.38% | -7,425.99% | -7,306.11% | -5,443.1% | - | - | -9,477.67% | - | - | - | -5,733.33% | -5,868.77% | -6,462.56% | -6,820% |
| Earnings before Tax (EBT) 1 | -4.658 | -3.228 | -3.271 | -5.076 | -4.554 | -4.596 | -5.121 | -7.661 | -4.697 | -4.709 | -5.082 | -5.505 | -6.236 | -6.767 |
| Net income 1 | -4.664 | -3.22 | -3.273 | -5.085 | -4.558 | -4.674 | -5.137 | -7.688 | -4.718 | -4.724 | -4.681 | -5.026 | -5.857 | -6.29 |
| Net margin | -17,051.3% | -7,451.82% | -7,270.92% | -5,347.44% | - | - | -9,310.11% | - | - | - | -5,201.39% | -5,291.05% | -6,007.18% | -6,290% |
| EPS 2 | -0.3900 | -0.2600 | -0.2800 | -0.4300 | -0.3800 | -0.3900 | -0.4300 | -0.6200 | -0.3700 | -0.2900 | -0.3160 | -0.3140 | -0.3200 | -0.3480 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-12 | 22-03-24 | 22-05-16 | 22-08-08 | 22-11-10 | 23-03-23 | 23-05-12 | 23-08-10 | 23-11-14 | 24-03-26 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -12.5 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | 0.09 | - | - | - | - | - |
| Capex / Sales | - | 57.1% | - | - | - | - | - |
| Announcement Date | 21-03-15 | 22-03-24 | 23-03-23 | 24-03-26 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.96
USD
Average target price
8.8
USD
Spread / Average Target
+197.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.34% | 53.43M | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- GANX Stock
- Financials Gain Therapeutics, Inc.
